Shindou T, Mori A, Kase H, Ichimura M
OctoberDecember 2025: imlunestrant Imlunestrant, a next-generation, brain-penetrant, oral selective estrogen receptor degrader (SERD) by Eli Lilly, is awaiting FDA approval for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer
Liquid formulations of certain GLP-1 receptor agonists
Ann Intern Med 146:477-485, 2007
It signals the brain to reduce hunger, allowing individuals to feel full longer and eat less
USA-manufactured products typically undergo rigorous testing for: Heavy metal contamination Protein content accuracy Microbiological safety Third-party verification Timing is Key: When to Consume Protein The timing of protein consumption amplifies its benefits for weight loss